All In Biotech

Drug Trial Radar · NCT00245921

Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception

A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg in a Continuous Daily Regimen for Oral Contraception

Last checked: Nov 20, 2026Latest source record: Feb 8, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,000

Actual

Start

Feb 2003

Primary completion

Oct 2005

Study completion Oct 2005

Sponsor

Sponsor type
Industry
First posted
Oct 28, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
None
Who can join
Female only, from 18 years, up to 49 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and contraceptive efficacy of an oral contraceptive containing a combination of LNG 90 mg/EE 20 mg in a continuous-use regimen.

Conditions

  • Contraception

Interventions

  • Levonorgestrel 90 mg/Ethinyl Estradiol 20 mgDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate safety and contraceptive efficacy

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.